Monsanto Settles Billion-Dollar Deal Over Glyphosate Lawsuits - Bayer's $7.25B glyphosate settlement aims to end decades of cancer lawsuits
Bayer's subsidiary Monsanto has agreed to a multi-billion-dollar settlement in the U.S. to resolve lawsuits over its glyphosate-based herbicide, Roundup. The deal, worth up to $7.25 billion (€6.13 billion), aims to end tens of thousands of pending and future claims linking the chemical to health risks. Critics have long opposed glyphosate, citing environmental damage and possible cancer risks.
The proposed class-action settlement would see Bayer pay out funds over a period of up to 21 years. Payments would decrease each year and remain subject to a cap, giving the company more control over its legal costs. Law firms representing the plaintiffs have already filed a motion for preliminary approval in a St. Louis, Missouri court.
Bayer CEO Bill Anderson described the agreement as a way to move past the legal uncertainty surrounding glyphosate. He emphasised the need to resolve disputes quickly and securely. Despite the settlement, the company continues to deny any wrongdoing, insisting it is only settling to end litigation—not admitting liability.
Glyphosate, the active ingredient in Roundup, has faced years of opposition from consumer and environmental groups. Protests have centred on its alleged links to cancer and ecological harm. The number of individual lawsuits settled before this announcement remains unclear, but the new deal covers both existing and potential future claims.
The settlement provides Bayer with a structured way to manage ongoing litigation costs while avoiding prolonged legal battles. If approved, it will close a long-running chapter of disputes over glyphosate's safety. The company now awaits court confirmation before the agreement takes effect.
